HK Stock Market Move | ZHAOKE OPHTH-B(06622) rose more than 5% in midday trading. The drug Cristabetin, which is used to treat glaucoma, has been approved for market launch.

09:52 20/09/2024

Tricorono Eye Clinic-B (06622) rose more than 5% intraday, and as of the time of writing, rose by 3.7% to 1.4 Hong Kong dollars, with a trading volume of 496,500 Hong Kong dollars.

, ZHAOKE OPHTH-B (06622) rose more than 5% during trading hours, and as of the time of writing, it has increased by 3.7% to 1.4 Hong Kong dollars, with a turnover of 496,500 Hong Kong dollars. On the news front, Zhaoke Ophthalmology announced this morning that its anti-glaucoma drug Bymicrontal prostaglandin eye drops (Crystalbet Clear) developed and produced by the company has been approved for listing by the National Medical Products Administration. It is reported that Bymicrontal prostaglandin eye drops (Crystalbet Clear) is the first single dosage prostaglandin eye drops in China without preservatives, used to reduce eye pressure in patients with angle-closure glaucoma and high eye pressure.

ST Holdings (08305) issued a profit warning, expecting the comprehensive loss for the year 2025 to increase by no less than 19 million Hong Kong dollars compared to the previous year.

CLOVER BIO-B(02197): Clover Hong Kong has entered into a settlement agreement with the Global Vaccine Immunization Alliance.

NEW GONOW RV (00805) is expected to have a net profit of approximately 31 to 40 million yuan in the fiscal year 2025, a year-on-year decrease of about 12.07% to 31.85%.

ST Holdings (08305) issued a profit warning, expecting the comprehensive loss for the year 2025 to increase by no less than 19 million Hong Kong dollars compared to the previous year.

CLOVER BIO-B(02197): Clover Hong Kong has entered into a settlement agreement with the Global Vaccine Immunization Alliance.

NEW GONOW RV (00805) is expected to have a net profit of approximately 31 to 40 million yuan in the fiscal year 2025, a year-on-year decrease of about 12.07% to 31.85%.